Ycanth

(Cantharidin)

Phase 1Small molecule

VVerrica Pharmaceuticals Inc.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Inflammation

NCT05597098

Clinical

Trials by Indication[1]

Safety and Efficacy2 trials

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

Completed·SSteven R Cohen·Phase 2·NCT03017846·30 enrolled

Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum

Completed·MMontefiore Medical Center·Phase 2·NCT02665260·94 enrolled

Cardiovascular Function1 trial

Investigation of the Influence of Gender on Cardiovascular Function

Completed·QQueen Mary University of London·Phase 1·NCT01582321·56 enrolled

Age1 trial

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT03306589·12 enrolled

Treatment1 trial

Cantharone for the Treatment of Perenial Warts

Completed·WWayne State University·Phase 4·NCT03625960·12 enrolled

Inflammation1 trial

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women: RESOLVE-SEX

Active, not recruiting·QQueen Mary University of London·Phase 1·NCT05597098·34 enrolled

1 more indication

Unspecified1 trial

Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT01762787·40 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 21, 2023

YCANTH

NDA NDA212905

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Cantharidin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cantharidin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cantharidin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA212905). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Ycanth. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Verrica Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVerrica Pharmaceuticals Inc.

Patent Landscape[5]

Patent Cliff

May 28, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11052064May 28, 2035

12233042Aug 22, 2038

11147790Aug 22, 2038

12290651Feb 19, 2041